重组链激酶与尿激酶治疗急性心肌梗死的对比研究

A Comparative Study on Recombinant Streptokinase and Urokinase in Treatment of Acute Myocardial Infarction

关键词:  链激酶  尿激酶  急性心肌梗死

Key words:  streptokinase  urokinase  acute myocardial infarction

摘要:

目的观察重组链激酶（r-SK）与尿激酶(UK)静脉溶栓治疗急性心肌梗死的疗效。方法将93患者随机分成r-SK组48例和UK组45例，均给常规治疗，r-SK组，r-SK150万单位+5％葡萄糖100 mL；UK组，UK150万单位+5％葡萄糖100 mL，观察冠状动脉再通率、不良反应及5周病死率。结果r-SK组总再通率81.25%，6 h内再通率为86.49%，与UK组比较，差异均有统计学意义（P<0.05）；2组在出血、心律失常、过敏、低血压及5周后死亡率上，差异无统计学意义（P>0.05）。结论r-SK较UK的心肌梗死血管再通率高，药效较好，也具有不良反应和并发症少的特点，是值得临床上推广应用。

Abstract:

OBJECTIVE To observe the effects of recombinant streptokinase (r-SK) and urokinase (UK) in treatment of acute myocardial infarction through intravenous thrombolysis. METHODS The 186 patients were randomly divided into Group r-SK (96 patients) and Group UK (90 patients).The patients of the both groups were given conventional therapy: Group r-SK was treated with r-SK (1 500 000 units) plus glucose solution (5%, 100 mL), while Group UK was treated with UK (1 500 000 units) plus glucose solution (5%, 100 mL). After that, the coronary recanalization rate, adverse reactions and mortality in 5 weeks were observed. RESULTS For Group r-SK, the general recanalization rate of is 81.25%, the recanalization rate in 6 hours is 85.14%, and the recanalization rate in 6-12 hours is 68.18%, each of which is significantly different from that of Group UK (P<0.05). However, there is no significant difference in bleeding, arrhythmia, allergy, low blood pressure and mortality after five weeks between the two groups (P>0.05). CONCLUSIONS Compared to UK, r-SK can achieve a higher rate of recanalization of myocardial infarction vessels, better treatment effect, and fewer adverse reactions and complications, so it's worth promoting in clinical treatment.